How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,411 results for

Clinical Institute Withdrawal Assessment for Alcohol

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Clinical Institute Withdrawal Assessment for Alcohol–Revised might be an unreliable tool in the management of alcohol withdrawal (PubMed)

Clinical Institute Withdrawal Assessment for Alcohol–Revised might be an unreliable tool in the management of alcohol withdrawal 28904034 2018 06 15 2018 11 13 1715-5258 63 9 2017 09 Canadian family physician Medecin de famille canadien Can Fam Physician Clinical Institute Withdrawal Assessment for Alcohol-Revised might be an unreliable tool in the management of alcohol withdrawal. 691-695 Knight Erin E Family physician and addiction medicine physician in Winnipeg, Man. At the time (...) in Vancouver. eng R25 DA037756 DA NIDA NIH HHS United States Case Reports Journal Article Canada Can Fam Physician 0120300 0008-350X 0 Hypnotics and Sedatives O26FZP769L Lorazepam Q3JTX2Q7TU Diazepam IM Alcohol Withdrawal Delirium drug therapy Clinical Protocols Communication Barriers Diazepam therapeutic use Humans Hypnotics and Sedatives administration & dosage therapeutic use Language Lorazepam therapeutic use Male Middle Aged 2017 9 15 6 0 2017 9 15 6 0 2018 6 16 6 0 ppublish 28904034 63/9/691

Full Text available with Trip Pro

2017 Canadian Family Physician

2. Evaluating nursing satisfaction and utilization of the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar) (PubMed)

Evaluating nursing satisfaction and utilization of the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar) The Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar), developed and validated for research, is used in our inpatient academic medical center. We sought to assess nursing satisfaction with the scale itself, training for using the scale, and nursing staff use of the CIWA-Ar.A retrospective chart review included all patients (...) of lorazepam. Lorazepam was not given to 21% of patients when they scored >8 on the CIWA-Ar, whereas 71% of patients received a dose of lorazepam when they had a CIWA score <8. The survey was sent to 2011 clinical nurses, with 284 responses received (14% response rate). Only 36% of responding nurses felt adequately trained to administer the CIWA-Ar. Most nurses preferred on-the-job and online training methods.Nursing use of the CIWA-Ar could be optimized at this institution. Fewer than half of respondents

Full Text available with Trip Pro

2016 The Mental Health Clinician

3. Clinical Institute Withdrawal Assessment for Alcohol

Clinical Institute Withdrawal Assessment for Alcohol Clinical Institute Withdrawal Assessment for Alcohol Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse (...) Cancer Administration 4 Clinical Institute Withdrawal Assessment for Alcohol Clinical Institute Withdrawal Assessment for Alcohol Aka: Clinical Institute Withdrawal Assessment for Alcohol , CIWA-Ar , CIWA Score II. Indications: Alcohol Detoxification assessment Scale used to direct protocol III. Technique Each criteria rated on scale of 0 to 7 (except orientation) Maximum score: 67 IV. Evaluation: Criteria , Score 0: None Score 4: Intermittent Score 7: Constant Score 0: None Score 4: with arms

2018 FP Notebook

4. Symptom-triggered therapy for assessment and management of alcohol withdrawal syndrome in the emergency department short-stay clinical decision unit. (PubMed)

for admission to CDU in those who required STT. Median Alcohol Use Disorders Identification Test score was 25 and 112 patients (64%) had at least one Clinical Institute Withdrawal Assessment for Alcohol revised measurement ≥10, triggering a dose of diazepam (20 mg). The median cumulative oral diazepam dose was 20 mg while 24 (15%) patients received a cumulative dose of 100 mg or more. Median time for STT was 12 hours (IQR=12, R=1-48). 3% (n=5) of patients required further general hospital admission (...) Symptom-triggered therapy for assessment and management of alcohol withdrawal syndrome in the emergency department short-stay clinical decision unit. We previously reported that benzodiazepine detoxification for alcohol withdrawal using symptom-triggered therapy (STT) with oral diazepam reduced length of stay (LOS) and cumulative benzodiazepine dose by comparison with standard fixed-dose regimen. In this study, we aim to describe the feasibility of STT in an emergency department (ED) short-stay

Full Text available with Trip Pro

2018 Emergency Medicine Journal

5. Baclofen for alcohol withdrawal. (PubMed)

with AWS. We excluded uncontrolled, non-randomised, or quasi-randomised trials. We included both parallel group and cross-over studies.We used standard methodological procedures expected by Cochrane.We included three RCTs with 141 randomised participants. We did not perform meta-analyses due to the different control interventions. For the comparison of baclofen and placebo (1 study, 31 participants), there was no significant difference in Clinical Institute Withdrawal Assessment of Alcohol Scale (...) Baclofen for alcohol withdrawal. Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4.To assess the efficacy and safety of baclofen for people with AWS.We updated our searches of the following databases to March 2017

Full Text available with Trip Pro

2017 Cochrane

6. Effect of intranasal oxytocin on alcohol withdrawal syndrome: A randomized placebo-controlled double-blind clinical trial. (PubMed)

trial with 40 patients fulfilling criteria for ICD-10 diagnosis of alcohol dependence (F10.2), admitted for alcohol detoxification and withdrawal treatment. The benzodiazepine oxazepam was given as symptom-triggered treatment based on the scores of the Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) scale. Participants were randomized to receive either intranasal oxytocin (24 IU twice daily) or placebo.Oxazepam dose required to complete a three-day course (...) Effect of intranasal oxytocin on alcohol withdrawal syndrome: A randomized placebo-controlled double-blind clinical trial. In a pilot study, intranasal oxytocin was demonstrated to reduce the benzodiazepine dose needed to relieve withdrawal symptoms during alcohol detoxification. The aim of the present study was to compare the effect of oxytocin and placebo during a three-day period of alcohol detoxification at an addiction treatment center in Norway.Randomized, double-blind, placebo-controlled

2019 Drug and alcohol dependence Controlled trial quality: predicted high

7. Alcohol Withdrawal Protocols for Acute Care Inpatients: Clinical Effectiveness and Guidelines

and should be individualized for each patient. 6 Symptom-triggered regimens are appropriate for many hospitalized patients, 4,5 and appropriate withdrawal scales (such as the Clinical Institute Withdrawal Assessment- Alcohol) should be used to guide clinical decision-making. 5 In patients with co-morbid conditions that may invalidate withdrawal scales, symptom- triggered regimens may not be appropriate. 5 Thiamine supplementation is recommended for patients undergoing alcohol withdrawal, 5 especially (...) : diagnosis, assessment and management of harmful drinking and alcohol dependence [Internet]. Leicester (UK): British Psychological Society; 2011. (National clinical practice guideline no. 115). [cited 2012 Dec 11]. Available from: http://www.nice.org.uk/nicemedia/live/13337/53190/53190.pdf 4. National Clinical Guideline Centre for Acute and Chronic Conditions. Alcohol-use disorders: diagnosis and clinical managment of alcohol-related physical complications [Internet]. London: National Institute

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Outcomes After Implementation of an Alcohol Withdrawal Protocol at a Single Institution (PubMed)

Outcomes After Implementation of an Alcohol Withdrawal Protocol at a Single Institution Background: There are varying dosing strategies for the administration of benzodiazepines in the setting of alcohol withdrawal. In October 2014, a symptom-based alcohol withdrawal protocol (AWP) using the Clinical Institute Withdrawal Assessment of Alcohol, Revised (CIWA-Ar) scale was implemented at one institution. Objective: To evaluate the safety and efficacy of the AWP. Methods: Retrospective chart (...) review was completed, including patients receiving at least one dose of diazepam for alcohol withdrawal pre- and post-protocol. The primary outcome of this study was the average daily and cumulative dose of diazepam during hospital stay. Secondary outcomes included length of stay and occurrence of seizures or delirium tremens. Results: The average daily dose and the average cumulative dose of diazepam were significantly lower in the post-protocol group (5.4 vs 12.1 mg, p < .001; 35.0 vs 77.6 mg, p

Full Text available with Trip Pro

2016 Hospital pharmacy

9. MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)

to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used. Other Name: Placebo Outcome Measures Go to Primary Outcome Measures : Between-group absolute difference of the CIWA-Ar score (revised clinical institute withdrawal assessment for alcohol scale) change from baseline [ Time Frame: 3 days after randomization ] Secondary Outcome Measures : Total benzodiazepine consumption compared between experimental and control groups throughout (...) at the Charlson Comorbidity Index (CCI) min-score at the CCI median versus score score at the CCI median-score at the CCI min [ Time Frame: 3 days after randomization ] Between-group absolute difference of the CIWA-Ar score (revised clinical institute withdrawal assessment for alcohol scale) change from baseline considering two subgroups: 18-59 years versus 60-75 years [ Time Frame: 3 days after randomization ] The number of participants who left the hospital against medical advice during the study compared

2017 Clinical Trials

10. Baclofen for alcohol withdrawal. (PubMed)

by an independent party. We contacted study authors for additional information where needed. We collected adverse effects information from the trials.Two RCTs with a total of 81 participants were eligible according to the inclusion criteria. One study suggested that both baclofen and diazepam significantly decreased the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) score, without any significant difference between the two interventions. The other study showed no significant (...) Baclofen for alcohol withdrawal. The treatment baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane review published in Issue 2, 2013.To assess the efficacy and safety of baclofen for people with AWS.We searched the Cochrane Drugs and Alcohol Group

Full Text available with Trip Pro

2015 Cochrane

11. Alcohol Withdrawal Management for Acute Care Inpatients

therapy AWS = alcohol withdrawal syndrome; BZD or BZO = benzodiazepines; CIWA-Ar = clinical institute withdrawal assessment of alcohol scale revised score; GHB = gamma-hydroxybutyric acid. Alcohol Withdrawal Management for Acute Care Inpatients 4 REFERENCES SUMMARIZED Health Technology Assessments No literature identified. Systematic Reviews and Meta-analyses 1. Awissi DK, Lebrun G, Coursin DB, Riker RR, Skrobik Y. Alcohol withdrawal and delirium tremens in the critically ill: a systematic review (...) management options for alcohol withdrawal Comparator No comparator Outcomes Evidence-based guidelines Study Designs Health technology assessment reports, systematic reviews, meta-analyses, evidence-based guidelines RESULTS Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by evidence-based guidelines. Five systematic reviews, including

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis. (PubMed)

on benzodiazepine requirements, alcohol withdrawal symptoms, and hospital length of stay in patients hospitalized with AWS.Retrospective cohort study.Large academic medical center.All adults presenting to the emergency department between January 2015 and April 2018 with a diagnosis of severe AWS (Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised [CIWA-Ar] score ≥ 15) and prescribed the institution's alcohol withdrawal agitated delirium protocol were eligible for inclusion in the study (...) High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis. Gabapentin has been proved to be beneficial in promoting abstinence, decreasing alcohol cravings, and improving mood and sleep quality when given at higher doses; however, data are limited regarding the efficacy and safety of using high-dose gabapentin as part of the treatment of alcohol withdrawal syndrome (AWS). The aim of this study was to evaluate the impact of high-dose gabapentin

2019 Pharmacotherapy

13. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. (PubMed)

interventions. The severity of alcohol dependence was assessed by using the Severity of Alcohol Dependence Questionnaire, and alcohol withdrawal was assessed with the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar).Sixty-six patients were randomized (baclofen n = 34, benzodiazepine (BZD) group n = 32). Two patients (one patient in each group) had complicated withdrawal symptoms and were dropped from the final analysis. There was a significant reduction in alcohol withdrawal symptoms (...) Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. Benzodiazepines (BDZs) have been the treatment of choice for alcohol withdrawal syndrome (AWS); however, they are associated with several side effects and also have abuse potential. In some studies, the use of baclofen has been effective in reducing symptoms of alcohol withdrawal symptoms.The objective of this study was to compare the efficacy of baclofen and benzodiazepine (lorazepam) in reducing

2019 Indian journal of psychiatry Controlled trial quality: uncertain

14. Alcohol Withdrawal Syndrome in Critically Ill Patients: Identification, Assessment, and Management. (PubMed)

. However, if patients progress to more severe withdrawal or delirium tremens, extra adjunctive medications in addition to benzodiazepines may be required. Sedation and mechanical ventilation may also be necessary. Withdrawal assessment scales such as the Clinical Institute of Withdrawal Assessment are of limited use in these patients. Instead, general sedation-agitation scales and delirium detection tools have been used. The important facets of care are the rapid identification of at-risk patients (...) Alcohol Withdrawal Syndrome in Critically Ill Patients: Identification, Assessment, and Management. Management of alcohol withdrawal in critically ill patients is a challenge. The alcohol consumption histories of intensive care patients are often incomplete, limiting identification of patients with alcohol use disorders. Abrupt cessation of alcohol places these patients at risk for alcohol withdrawal syndrome. Typically benzodiazepines are used as first-line therapy to manage alcohol withdrawal

Full Text available with Trip Pro

2016 Critical care nurse

15. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence

outcome measure SADQ or LDQ for severity of dependence Clinical Institute Withdrawal Assessment of Alcohol Scale, revised (CIWA-Ar) for severity of withdrawal APQ for the nature and extent of the problems arising from alcohol misuse. 1.2.1.5 When assessing the severity of alcohol dependence and determining the need for assisted withdrawal, adjust the criteria for women, older people, children and young people [4] , and people with established liver disease who may have problems with the metabolism (...) to the settings (for example, inpatient or community) in which the withdrawal is managed. 1.2.1.7 Staff treating people with alcohol dependence presenting with an acute unplanned alcohol withdrawal should refer to 'Alcohol-use disorders: diagnosis and clinical management of alcohol-related physical complications' (NICE clinical guideline 100). 1.2.2 1.2.2 Assessment in specialist alcohol services Assessment in specialist alcohol services T T reatment goals reatment goals 1.2.2.1 In the initial assessment

2011 National Institute for Health and Clinical Excellence - Clinical Guidelines

16. Magnesium for alcohol withdrawal. (PubMed)

ranging from 12.5 mmol/day to 20 mmol/day. One trial studied parenteral magnesium (16.24 mEq q6h for 24 hours). Each trial demonstrated a high risk of bias in at least one domain. There was significant clinical and methodological variation between trials.We found no study that measured all of the identified primary outcomes and met the objectives of this review. Only one trial measured clinical symptoms of seizure, delirium tremens or components of the Clinical Institute Withdrawal Assessment (...) Magnesium for alcohol withdrawal. Patients have been given magnesium to treat or prevent alcohol withdrawal syndrome (AWS). Evidence to support this practice is limited, and is often based on the controversial link between hypomagnesaemia and AWS.To assess the effects of magnesium for the prevention or treatment of AWS in hospitalised adults.We searched the Cochrane Drugs and Alcohol Group Register of Controlled Trials (August 2012), PubMed (from 1966 to August 2012 ), EMBASE (from 1988

2013 Cochrane

17. Baclofen for alcohol withdrawal. (PubMed)

the trials.We identified a total of 113 references from all electronic databases searched excluding duplicates. After screening of titles and abstracts, full papers of 10 studies were obtained and assessed for eligibility. Finally, two RCTs with 81 participants were eligible according to the inclusion criteria. Regarding the efficacy, one study suggested that both baclofen and diazepam significantly decreased the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) score, without any (...) Baclofen for alcohol withdrawal. The treatment baclofen can rapidly reduce symptoms of severe alcohol withdrawal syndrome (AWS) in alcoholic patients, with a significant reduction in the cost. Baclofen is easy to manage, and rare euphoria, craving and other pleasant effects are reported by patients treated with baclofen.To assess the efficacy and safety of baclofen for patients with AWS.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (October

2013 Cochrane

18. Alcohol Use and Pregnancy Consensus Clinical Guidelines

Alcohol Use and Pregnancy Consensus Clinical Guidelines No. 245-Alcohol Use and Pregnancy Consensus Clinical Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 39, Issue 9, Pages e220–e254 No. 245-Alcohol Use and Pregnancy Consensus Clinical Guidelines x George Carson , MD, FRCSC Regina, SK x Lori Vitale Cox , PhD Elsipogtog, NB x Joan Crane , MD, FRCSC St. John’s, NL x Pascal Croteau , MD, CCFP Shawville, QC (...) Source: Sokol RJ, Martier SS, Ager JW. The T-ACE questions: practical prenatal detection of risk-drinking. American Journal of Obstetrics and Gynecology, 1989;160(4):863-870. Figure 6 The TWEAK tool. 25 Source: Russell M. New assessment tools for risk drinking during pregnancy: T-ACE, TWEAK and Others. Alcohol Health and Research World 1994;18(1):55-61. Abstract Objective To establish national standards of care for the screening and recording of alcohol use and counselling on alcohol use of women

2017 Society of Obstetricians and Gynaecologists of Canada

19. Correlation Between mMINDS and CIWA-Ar Scoring Tools in Patients With Alcohol Withdrawal Syndrome. (PubMed)

Correlation Between mMINDS and CIWA-Ar Scoring Tools in Patients With Alcohol Withdrawal Syndrome. Many alcohol withdrawal scoring tools are used in hospitalized patients to assess the severity of alcohol withdrawal and guide treatment. The revised Clinical Institute Withdrawal Assessment (CIWA-Ar) and the modified Minnesota Detoxification Scale (mMINDS) are commonly used but have never been correlated.To determine the strength of correlation between the CIWA-Ar and mMINDS scoring tools (...) in patients with alcohol withdrawal syndrome.A single-center, prospective correlation study conducted at a large academic medical center. Patients treated for alcohol withdrawal syndrome according to the Yale Alcohol Withdrawal Protocol were identified daily, and both the CIWA-Ar and mMINDS were administered at each time point required by the protocol. Clinical data were obtained from the electronic medical records.A total of 185 CIWA-Ar and mMINDS scores were collected in 30 patients. The Pearson

2018 American Journal of Critical Care

20. Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the emergency department. (PubMed)

. Adult patients seen in the ED with a diagnosis of alcohol withdrawal syndrome were included. Patients were categorized into two groups based on whether phenobarbital was administered in the ED: 1) phenobarbital group (with or without benzodiazepines) or 2) non-phenobarbital group. The primary outcome measure was the need for ICU admission. Secondary outcomes included Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores at ED discharge, and complications. Complications were (...) Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the emergency department. To compare a phenobarbital-adjunct versus benzodiazepine-only approach for the management of alcohol withdrawal syndrome in the emergency department (ED) with regard to the need for intensive care unit (ICU) admission, severity of symptoms on ED discharge, and complications.This was a retrospective cohort study conducted in two academic EDs in the United States

2018 American Journal of Emergency Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>